Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALEVE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Relief of symptoms of seasonal allergic rhinitis such as sneezing, rhinorrhea, and nasal congestion,Relief of nasal congestion due to common cold or upper respiratory allergies
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Cetirizine: terminal half-life ~8.3 hours in healthy adults (prolonged to 20-30 hours in renal impairment). Pseudoephedrine: terminal half-life ~4-8 hours (p H-dependent urinary excretion; prolonged in alkaline urine).
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Cetirizine undergoes minimal hepatic metabolism via oxidation to an inactive metabolite, primarily excreted unchanged in urine. Pseudoephedrine is partially metabolized in the liver by N-demethylation to an active metabolite, with about 50-75% excreted unchanged in urine.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Cetirizine: approximately 70% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% in feces. Pseudoephedrine: 70-90% excreted unchanged in urine; remainder as inactive metabolites.
>99% bound to albumin; saturable at high concentrations.
Cetirizine: 93% bound to albumin. Pseudoephedrine: not significantly protein bound (<10%).
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Cetirizine: 0.5-0.8 L/kg (total body water). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: ~95%; immediate-release formulation.
Cetirizine: oral bioavailability ~70% (not affected by food). Pseudoephedrine: oral bioavailability ~100% (first-pass metabolism minimal).
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
GFR 30-49 m L/min: 1 tablet every 24 hours. GFR <30 m L/min or dialysis: contraindicated.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Child-Pugh A or B: no dose adjustment required. Child-Pugh C: contraindicated due to lack of data.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Children <12 years: not approved. Children ≥12 years: same as adult dosing (5 mg/120 mg every 12 hours).
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Use with caution; start with 1 tablet every 24 hours due to increased sensitivity and risk of anticholinergic effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
None
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Cardiovascular effects: Use with caution in patients with hypertension, cardiovascular disease, or ischemic heart disease due to pseudoephedrine's vasoconstrictive and positive chronotropic effects,Cerebrovascular effects: Pseudoephedrine may cause ischemic colitis, hemorrhagic stroke, or vasospasm; avoid in patients with history of stroke or vasculopathy,Nervous system effects: May cause insomnia, nervousness, or seizure; use with caution in elderly or those with seizure disorders,Renal impairment: Dose adjustment for cetirizine necessary in moderate to severe renal impairment,Drug interactions: Avoid MAO inhibitors or use within 14 days; concomitant use with other sympathomimetics may increase adverse effects
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Hypersensitivity to cetirizine, pseudoephedrine, or any components,Severe hypertension or coronary artery disease,Use of monoamine oxidase inhibitors (MAOIs) currently or within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <10 m L/min) for cetirizine component
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
No significant food interactions. Avoid concurrent use of caffeine or other stimulants (e.g., coffee, tea, energy drinks) as pseudoephedrine may additive CNS stimulation. Take without regard to meals; fatty meals may delay absorption of cetirizine but not clinically relevant.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avoid first trimester. Second/third trimester: no known fetal risks; monitor for reduced uterine blood flow due to vasoconstriction.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Small amounts excreted in breast milk. M/P ratio not established for combination. Cetirizine M/P ~0.25-1.3. Pseudoephedrine M/P ~2.6-3.5; may reduce milk production. Use with caution, especially in preterm infants. Monitor infant for irritability, sleep disturbance.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
No pharmacokinetic changes requiring routine dose adjustment in pregnancy. However, increased renal clearance may reduce cetirizine levels; clinical significance unclear. Avoid excessive pseudoephedrine due to vasoconstriction; use lowest effective dose.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Cetirizine/pseudoephedrine combines a second-generation antihistamine with a sympathomimetic decongestant. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in hyperthyroidism, diabetes, and prostate hyperplasia. Monitor for CNS stimulation (insomnia, nervousness) especially in evening dosing. Cetirizine is less sedating than first-generation antihistamines but may still cause drowsiness; pseudoephedrine can counteract sedation. Contraindicated with MAOIs or within 14 days of use. Not recommended in pregnancy category B (cetirizine) but pseudoephedrine crosses placenta; avoid in lactation.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
Take this medication by mouth with or without food, with a full glass of water.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol, as it can increase drowsiness and side effects.,May cause drowsiness or dizziness; use caution when driving or operating machinery.,Do not exceed recommended dose; do not take more than every 12 hours.,Report rapid or irregular heartbeat, chest pain, or severe dizziness.,Discontinue use and consult doctor if symptoms persist after 7 days or with fever.,Avoid taking with other cold, allergy, or sleep aids without approval.,If you have high blood pressure, heart disease, or urinary retention, consult doctor before use.,Store at room temperature, away from moisture and heat.
No interactions on record
"Normethadone, an opioid analgesic with QT-prolonging properties, combined with cetirizine, a second-generation antihistamine that can also prolong the QT interval, increases the risk of additive cardiotoxicity, specifically potentially fatal ventricular arrhythmias like torsade de pointes. This interaction is most concerning in patients with preexisting QT prolongation, electrolyte disturbances, or those taking other QT-prolonging agents. Clinical outcomes may include palpitations, syncope, or sudden cardiac death."
"Cetirizine is a second-generation antihistamine that selectively blocks peripheral H1 receptors, while cyproheptadine is a first-generation antihistamine with additional antiserotonergic and anticholinergic properties. When coadministered, additive central nervous system depression may occur, leading to excessive sedation, dizziness, and psychomotor impairment. Concurrent use also potentiates anticholinergic adverse effects such as dry mouth, urinary retention, and blurred vision, particularly in elderly patients."
"Concurrent use of flupentixol and cetirizine may result in additive central nervous system depression, including increased sedation, drowsiness, and psychomotor impairment. Flupentixol, a thioxanthene antipsychotic with prominent antihistaminergic (H1) and antidopaminergic effects, combined with cetirizine, a peripheral H1-antihistamine with limited central penetration but dose-related sedative potential, can lead to exaggerated CNS and respiratory depression, altered cognitive function, and reduced reaction time. These effects increase the risk of falls, accidents, and respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALEVE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, answered by our medical review team.
ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is a Sympathomimetic that works by Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALEVE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. The standard adult dose of CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is: 1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALEVE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is classified as Category A/B. Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.